Last reviewed: June 11, 2026
Last updated: June 11, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
GLP-1 medications have demonstrated effectiveness for weight management in clinical trials, with some patients losing 15-20% of body weight over 68 weeks. Qualification for these treatments depends on specific medical criteria rather than insurance coverage or membership fees. PlexusDx makes accessing compounded GLP-1 therapy straightforward across all 50 states.
Understanding GLP-1 Eligibility Requirements
GLP-1 receptor agonists qualify patients based on body mass index, weight-related health conditions, and medical history rather than insurance status. Most candidates fall into three categories: adults with a BMI of 30 or higher, adults with a BMI of 27 or higher plus weight-related conditions like type 2 diabetes or hypertension, or adults with a history of cardiovascular disease combined with overweight status. PlexusDx evaluates each patient individually through a consultation process that considers overall health, medications, and personal goals.
Medical conditions that support GLP-1 qualification include type 2 diabetes, high blood pressure, elevated cholesterol, sleep apnea, and joint problems linked to excess weight. Previous weight loss attempts and their outcomes also inform eligibility decisions. Unlike traditional insurance-based restrictions, PlexusDx removes financial barriers by offering compounded semaglutide injections starting at $149 monthly with no membership requirements, making treatment accessible regardless of insurance coverage.
BMI and Weight-Related Health Conditions
Body mass index serves as one screening tool but not the sole qualification measure. A BMI of 30 or above generally qualifies patients for GLP-1 treatment, while a BMI between 27 and 29.9 combined with obesity-related conditions also meets criteria. Obesity-related conditions include hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, and cardiovascular disease. These conditions create health risks that weight loss through GLP-1 therapy can meaningfully reduce.
Weight-related complications extend beyond standard BMI calculations and include metabolic syndrome, insulin resistance, and fatty liver disease. Patients with family histories of heart disease or diabetes often qualify for preventive GLP-1 treatment. PlexusDx consultations explore these nuanced health factors to ensure personalized treatment matching individual needs rather than applying one-size-fits-all eligibility rules.
Medical History and Medication Interactions
Your complete medical history determines GLP-1 safety and suitability for your specific situation. Certain conditions contraindicate GLP-1 use, including personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and severe diabetic retinopathy. Current medications require review because GLP-1 compounds can interact with insulin, sulfonylureas, and other diabetes medications, potentially requiring dose adjustments. Gallbladder disease history, pancreatitis, and gastrointestinal disorders warrant careful evaluation.
PlexusDx providers conduct thorough medication reviews during qualification consultations to identify potential interactions and safety concerns. This detailed assessment prevents complications and ensures semaglutide or tirzepatide injections work safely alongside your current treatment plan. Patients with stable chronic conditions like managed hypertension or controlled hypothyroidism typically qualify with appropriate monitoring.
How PlexusDx Qualification Works
PlexusDx streamlines the qualification process by connecting patients with licensed practitioners who evaluate eligibility through telehealth consultations. You complete a detailed health questionnaire covering medical history, current medications, weight goals, and lifestyle factors. A PlexusDx-affiliated physician reviews your information, determines qualification status, and creates a personalized treatment plan if appropriate. This entire process occurs without insurance requirements, membership fees, or lengthy delays common to traditional healthcare.
Once qualified, patients choose from compounded formulations including semaglutide injections starting at $149 monthly across all commitment tiers, with no price increases as doses escalate. PlexusDx also offers the optional Precision Peptide Genetic Test for $99 after your first treatment month, which maps 14 metabolic pathways and 49 peptides to predict individual response patterns based on genetic variants in GLP1R, GIPR, FTO, and MC4R genes. HSA and FSA accounts cover all medications and testing, expanding affordability options.
Preparing for Your GLP-1 Qualification Consultation
Documentation accelerates your qualification process significantly. Gather recent lab work including fasting glucose, hemoglobin A1c, lipid panels, and thyroid function tests if available. List all current medications with dosages, including over-the-counter supplements and herbal products. Prepare a detailed weight history including previous attempts at weight loss and results. Document any weight-related health conditions, family history of diabetes or heart disease, and personal goals for treatment. This preparation helps PlexusDx providers make rapid, informed qualification decisions.
Your consultation represents an opportunity to discuss expectations, potential side effects, and personalized strategies for success. Be honest about dietary habits, activity levels, and barriers to weight loss you've encountered previously. Share any concerns about compounded medications or GLP-1 therapy generally. PlexusDx providers address all questions transparently, helping you understand that qualification depends on clinical appropriateness rather than marketing or profit-driven criteria.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Do I need insurance to qualify for GLP-1 medications through PlexusDx?
No. PlexusDx serves all 50 states without requiring insurance coverage or membership fees. Compounded semaglutide injections start at $149 monthly across all commitment tiers. HSA and FSA accounts are eligible, and many patients find self-pay pricing more affordable than insurance copays.
What BMI do I need to qualify for semaglutide treatment?
PlexusDx qualifies patients with a BMI of 30 or higher, or a BMI of 27-29.9 combined with weight-related health conditions like diabetes, hypertension, or sleep apnea. BMI serves as one screening tool, but medical history and individual health factors matter equally in qualification decisions.
Can I qualify for GLP-1 therapy if I have type 2 diabetes?
Yes. Type 2 diabetes is a weight-related condition that supports GLP-1 qualification regardless of BMI. PlexusDx providers carefully review your diabetes medications during consultation to ensure safe combination therapy and appropriate dose adjustments if needed.
What medical conditions prevent me from qualifying for GLP-1 medications?
Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 contraindicate GLP-1 use. Severe diabetic retinopathy, active pancreatitis, and certain gastrointestinal disorders warrant careful evaluation. PlexusDx providers conduct thorough screening to identify any contraindications.
How can the Precision Peptide Genetic Test help my GLP-1 qualification?
PlexusDx's Precision Peptide Genetic Test maps 14 metabolic pathways across 49 peptides, identifying genetic variants in GLP1R, GIPR, FTO, and MC4R that predict individual response patterns. This $99 test (available after your first treatment month) helps personalize medication selection and dosing strategy for optimal results.
How long does the PlexusDx qualification process take?
Most consultations occur within 48 hours of application. After your telehealth appointment with a licensed provider, qualified patients receive their first shipment of compounded medication within 5-7 business days. PlexusDx prioritizes rapid access without compromising clinical evaluation.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How Much Weight Do You Lose with Ozempic?
Navigating Semaglutide Dosing: Can You Take Your Shot Early?